IP Verse

Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases

Patent No. EP3131582 (titled "Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases") was filed by Vertex Pharmaceuticals Incorporated on Apr 14, 2015. The application was issued on May 23, 2018.

Patent Summary

Pharmaceutical compositions for treating CFTR-mediated diseases with improved properties. The compositions contain a mixture of therapeutic agents, including a CFTR corrector and a CFTR potentiator, in spray dried dispersion form. The dispersions are substantially free of polymer. The spray drying process helps to improve the properties of the therapeutic agents when combined in this way. The compositions can be used to treat cystic fibrosis by providing enhanced CFTR function.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKFeb 22, 2019TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3131582

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP15721912A
Filing Date
Apr 14, 2015
Status
Granted And Under Opposition
Apr 20, 2018
Publication Date
May 23, 2018
External Links
Slate, Register , Google Patents